Please use this identifier to cite or link to this item: https://hdl.handle.net/10216/138971
Full metadata record
DC FieldValueLanguage
dc.creatorSalehi, B
dc.creatorSelamoglu, Z
dc.creatorMileski, KS
dc.creatorPezzani, R
dc.creatorRedaelli, M
dc.creatorCho, WC
dc.creatorKobarfard, F
dc.creatorRajabi, S
dc.creatorMartorell, M
dc.creatorKumar, P
dc.creatorMartins, N
dc.creatorSantra, TS
dc.creatorSharifi-Rad, J
dc.date.accessioned2022-01-10T09:58:44Z-
dc.date.available2022-01-10T09:58:44Z-
dc.date.issued2019
dc.identifier.issn2218-273X
dc.identifier.urihttps://hdl.handle.net/10216/138971-
dc.description.abstractCancer is the second leading cause of death worldwide. The main modality to fight against cancer is surgery, radiotherapy, and chemotherapy, and more recently targeted therapy, gene therapy and immunotherapy, which play important roles in treating cancer patients. In the last decades, chemotherapy has been well developed. Nonetheless, administration of the drug is not always successful, as limited drug dosage can reach the tumor cells.. In this context, the possibility to use an encapsulated anti-cancer drug may potentially solve the problem. Liposomal cytarabine is a formulation with pronounced effectiveness in lymphomatous meningitis and reduced cardiotoxicity if compared to liposomal anthracyclines. Thus, the future liposomal cytarabine use could be extended to other diseases given its reduction in cytotoxic side effects compared to the free formulation. This review summarizes the chemistry and biology of liposomal cytarabine, with exploration of its clinical implications.
dc.description.sponsorshipN. Martins would like to thank the Portuguese Foundation for Science and Technology (FCT-Portugal) for the strategic project ref. UID/BIM/04293/2013 and "NORTE2020 - Programa Operacional Regional do Norte" (NORTE-01-0145-FEDER-000012). M. Martorell would like to thank the support offered by CONICYT PIA/APOYO CCTE AFB170007.
dc.language.isoeng
dc.publisherMDPI
dc.relationinfo:eu-repo/grantAgreement/FCT/5876/147342/PT
dc.relation.ispartofBiomolecules, vol.9(12):773
dc.rightsopenAccess
dc.rights.urihttps://creativecommons.org/licenses/by/4.0/
dc.subject.meshAnimals
dc.subject.meshAntineoplastic Agents / administration & dosage
dc.subject.meshAntineoplastic Agents / chemistry
dc.subject.meshCytarabine / administration & dosage
dc.subject.meshCytarabine / chemistry
dc.subject.meshDrug Compounding
dc.subject.meshHumans
dc.subject.meshLiposomes / chemistry
dc.subject.meshNeoplasms / drug therapy
dc.titleLiposomal cytarabine as cancer therapy: From chemistry to medicine
dc.typeArtigo em Revista Científica Internacional
dc.contributor.uportoInstituto de Investigação e Inovação em Saúde
dc.identifier.doi10.3390/biom9120773
dc.relation.publisherversionhttps://www.mdpi.com/2218-273X/9/12/773
Appears in Collections:I3S - Artigo em Revista Científica Internacional

Files in This Item:
File Description SizeFormat 
10.3390-biom9120773.pdf1.23 MBAdobe PDFThumbnail
View/Open


This item is licensed under a Creative Commons License Creative Commons